CEO Conversations XLV: Bora Pharmaceutical (6472 TT)— Insights from Alex Lee, Founder of QIC, and Bobby Sheng, Chairman of Bora Pharmaceutical

Alex Lee 2023-09-28

(Photo: TaiwanPlus)

This episode of CEO Conversations is edited and republished with permission from TaiwanPlus Point.

Over the past two decades, Taiwan has been continuously devoted to the development of the biotechnology and medical industry. As of the end of 2022, the total market value of the listed biotech industry in Taiwan has reached NT$ 1.47 trillion, with an overall profit of approximately NT$ 25 billion. Due to the limited domestic market in Taiwan, Taiwanese pharmaceutical companies have had to internationalize to thrive. Taiwan's pharmaceutical manufacturers are among the most densely certified by the US FDA FDA GMP inspections globally, producing at least several dozen international pharmaceutical active ingredients in Taiwan, which are sold in over 100 countries worldwide.

In recent years, Contract Development and Manufacturing Organizations (CDMOs) have become a focal point, especially with the outbreak of the COVID-19 pandemic, leading to a surge in demand for vaccines and essential medicines. CDMOs with the capability to design and manufacture have become a prominent player in the market.

Among them, Bora Pharmaceuticals not only stands as the largest capacity CDMO company in Taiwan but also possesses 7 production facilities globally, with over 1,200 multinational employees and supplying pharmaceutical products to over 100 companies worldwide. In the first eight months of 2023, Bora Pharmaceuticals generated a consolidated revenue of NT$9.98 billion (+195% YoY). Between 2017-2022, Bora Pharmaceuticals boasts a 5-year CAGR of 97% in revenue, 91% in gross profit, 172% in operating income, and 166% in net profits.

Today, we are honored to have Mr. Bobby Sheng, Chairman of Bora Pharmaceuticals, to share with us the impact and significance of the CDMO industry on the global pharmaceutical sector, Taiwan's crucial role in the world of pharmaceuticals, and Bora's strategies and future growth directions.

Taiwan Talks interview link: https://reurl.cc/dme48V

Alex Lee

Alex is a creative and passionate entrepreneur and CEO who founded QIC. At its core, QIC's ambition is to advise companies, founders, and global investors to maximize their shareholder values amidst the drastic transformation of businesses and capital markets in Asia. Before starting up QIC in 2012, he had successful careers in Asian equity, investment banking, and public policy advisory for 20 years with long-standing CEO roles at top-tier global and Asian investment banks, and board directors at many outstanding Asian financial institutions and technology companies.